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The 6-Minute Walk
Test as a Primary




“Golf is a good walk spoiled.”
—Mark Twain (1)
Walking is a basic form of locomotion that involves the
coordination of numerous muscles to provide forward
movement while maintaining body balance and limiting
energy expenditure (2). The distance and speed that a
healthy individual can walk is governed by many factors,
including age, sex, height (longer legs make longer strides),
weight, and motivation (3). For these reasons, it is hard to
know what normal walking is. Watch people walking to
work in the morning on a busy street in any large city, and
you will get a sense of the variety of walking styles.
See page 1192
In the presence of an underlying disease, the factors that
limit how quickly one can walk become more complex
because an impairment of any of the participating organ
systems may limit the overall ability to walk a specific
distance within a specific time. Although it may seem
counterintuitive, several studies have shown better correla-
tions between exercise tolerance and peripheral abnormali-
ties than hemodynamic abnormalities in patients with car-
diopulmonary disease (4). This is because changes that
occur in the periphery as a consequence of the systemic
effects of heart failure often become the factors limiting
exercise more than the heart dysfunction that initiated the
syndrome. Consequently, you may have better results im-
proving exercise tolerance in a patient with pulmonary
arterial hypertension (PAH) if you target your treatments to
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contents of this paper to disclose.increasing blood flow to exercising muscles than if you
target them to resting hemodynamics.
The first randomized controlled trial (RCT) for drug
registration for PAH was initiated in 1990 to evaluate the
efficacy and safety of intravenous epoprostenol (5). Al-
though the steering committee for that study suggested
hemodynamics as the primary endpoint, the Food and Drug
Administration insisted (correctly) that an acceptable pri-
mary endpoint needed to either be a measure of the patient’s
symptoms, exercise tolerance, or survival. The sponsor
(Burroughs Wellcome) was unwilling to make survival the
primary endpoint because it would have required a much
larger trial over a much longer period of time. The sponsor
was also reluctant to use functional class as the endpoint
because of its subjective nature. As a result, a measure of
exercise capacity was chosen. The steering committee,
which was composed of cardiologists and pulmonologists,
then debated which measure of exercise to use. The cardi-
ologists recommended a treadmill test because it was a
popular test for coronary artery disease (6) and it had been
used successfully in heart failure trials (7). The pulmonolo-
gists preferred the 6-min walk (6MW) test, which was just
being introduced as a clinical tool in patients with lung
disease (8), even though there were no data about its utility
in PAH. The pulmonologists major objection was that they
would have to coordinate the use of the treadmill with the
cardiology division in their medical centers. Because there
were more pulmonologists than cardiologists on the steering
committee, the quick show of hands resulted in the 6MW
test as the winner.
As is typical in clinical trials, because the 6MW test was
a successful primary endpoint in the first epoprostenol trial,
almost every subsequent registration trial evaluating pulmo-
nary vasodilators in PAH has also used the 6MW test as the
primary endpoint. It is not, and was never intended to be, a
surrogate for pulmonary hemodynamics or a measure of the
underlying pulmonary vascular disease. It is a test that
reflects activities of daily living and to the extent that 6MW
can be improved, it is a worthwhile metric.
Meta-analyses on the RCTs for PAH have reported that
in addition to improving 6MW distance, the pulmonary
vasodilators also reduce short-term mortality (9). In this
issue of the Journal, Savarese et al. (10) sought to determine
what the magnitude of change in the 6MW test represented
in patients with PAH. Because the individual RCTs were
not powered to detect differences in clinical events, they
performed a meta-analysis on 22 published trials involving
more than 3,000 patients. From the hypothesis that the
patients with better improvements would have better out-
comes, they were surprised to find no relationship between
the change in 6MW distance and mortality, lung transplan-
tation, hospitalization for pulmonary hypertension, or ini-
tiation of pulmonary hypertension rescue therapy. It is
curious that every RCT in PAH evaluating a pulmonary
vasodilator drug has resulted in similar increases in 6MW
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patients report is even noticeable (11). The following seem
to make little difference in the results: patient’s age, severity
of symptoms, hemodynamics, type of pulmonary hyperten-
sion, drug studied, or drug dosage. Remarkably, it appears
that if a pulmonary vasodilator results in any increase in
6MW distance, it will be associated with improved survival
over a 4-month period (9). What we do not know is why.
There is no debate that improving exercise capacity and
reducing mortality are worthwhile achievements for patients
with PAH. However, the current design of RCTs in this
illness has been woefully lacking with respect to identifying
other important endpoints that are affected, identifying
biomarkers that represent how the disease may be altered, or
showing that the durability of treatment effect will last
beyond 4 months. More disappointing, in my opinion, is
that none of the clinical trials has yet demonstrated the
mechanism of action of the treatments used in studied
patients with PAH. We do not know if endothelin receptors
were effectively blocked or whether endothelin receptor
blockade affects the pulmonary vasculature directly. Nor do
we know to what extent phosphodiesterase 5 was inhibited
in the lung or myocardium. Nor do we know if the
long-term benefits of prostacyclin are a result of its effects
on the pulmonary circulation or the myocardial circulation.
It remains a possibility that pulmonary vasodilators work
primarily on the peripheral circulation (12).
We have been challenged with trying to treat a progres-
sive and fatal illness that affects a relatively small number of
people with PAH and seem to be a long way from triumph.
Emerging pathology studies in patients with PAH who
have died while being treated with pulmonary vasodilators
have failed to show that the therapies protected the pulmo-
nary vasculature against progressive vascular changes
(13,14). For that reason, the RCTs for PAH in the future
have to be designed to assure that they will always succeed,
even if the treatments do not. By that I mean that we need
to advance our knowledge about the disease and the therapy
every time we conduct a study. This will require moving
away from the outdated traditional clinical trial design to
more novel trial strategies. For example, by pre-specifying
an analysis of specific subgroups in the RCTs, we may
identify patients with better responses, which can lead to the
development of more personalized treatments. Evaluating
novel biomarkers that represent our current understanding
of the disease pathobiology may validate them as surrogate
endpoints and allow for smaller studies in the future. And
measuring the response of the biological targets of the drug
in patients will lead to a better understanding of how drugsmay modify disease expression. It will take a coordinated
effort among the physicians, pharmaceutical companies, and
regulatory agencies to make this happen, and it will not be
a walk in the park. But we have the knowledge and means
to do it, and our patients clearly deserve it.
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